Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias

被引：0
|
作者：
Feldman, Eric J. [1 ]
Lancet, Jeffrey [2 ]
Kolitz, Jonathan E. [3 ]
Ritchie, Ellen [4 ]
List, Alan F. [2 ]
Asatiani, Ekatherine [5 ]
Curcio, Tania J. [1 ]
Burton, Michelle [2 ]
Fricano, Marge [3 ]
Swenson, Christine [6 ]
Mayer, Lawrence D. [6 ]
Louie, Arthur C. [6 ]
机构：
[1] New York Presbyterian Hosp, Cornell Med Ctr, New York, NY USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[3] N Shore Univ Hosp, Lake Success, NY USA
[4] Weill Cornell Med Coll, New York, NY USA
[5] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA
[6] Celator Pharmaceut Inc, Princeton, NJ USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1025 / 1025
页数：1
相关论文
共 17 条
  • [1] Phase I study of a liposomal carrier (CPX-351) containing an optimized, synergistic, fixed molar ratio of cytarabine (Ara-C) and daunorubicin (DNR) in advanced leukemias and myelodysplastic syndromes (MDS)
    Feldman, Eric J.
    Lancet, Jeffrey E.
    Kolitz, Jonathan E.
    Asatiani, Ekatherine
    Curcio, Tania J.
    Burton, Michelle K.
    Fricano, Marjorie
    Begley, Aman R.
    Swenson, Christine
    Mayer, Lawrence
    Janoff, Andrew S.
    Louie, Arthur C.
    BLOOD, 2007, 110 (11) : 274A - 275A
  • [2] PHARMACOLOGY OF CPX-351: A NANO-SCALE LIPOSOMAL FIXED MOLAR RATIO CYTARABINE-DAUNORUBICIN FOR PATIENTS WITH ADVANCED LEUKEMIA
    Feldman, E. J.
    Lancet, J. E.
    Kolitz, J. E.
    Trang, J. M.
    Mayer, I.
    Louie, A. C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 67 - 67
  • [3] Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia
    Feldman, E. J.
    Kolitz, J. E.
    Trang, J. M.
    Liboiron, B. D.
    Swenson, C. E.
    Chiarella, M. T.
    Mayer, L. D.
    Louie, A. C.
    Lancet, J. E.
    LEUKEMIA RESEARCH, 2012, 36 (10) : 1283 - 1289
  • [4] First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
    Feldman, Eric J.
    Lancet, Jeffrey E.
    Kolitz, Jonathan E.
    Ritchie, Ellen K.
    Roboz, Gail J.
    List, Alan F.
    Allen, Steven L.
    Asatiani, Ekatherine
    Mayer, Lawrence D.
    Swenson, Christine
    Louie, Arthur C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) : 979 - 985
  • [5] Pharmacokinetics of CPX-351: A nano-scale liposomal fixed molar ratio of cytarabine-daunorubicin (Cyt:Daun) in patients with advanced leukemia
    Feldman, Eric J.
    Lancet, Jeffrey E.
    Kolitz, Jonathan E.
    Trang, John M.
    Mayer, Lawrence D.
    Swenson, Chris E.
    Chiarella, Michael T.
    Louie, Arthur C.
    CANCER RESEARCH, 2011, 71
  • [6] Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
    Lancet, Jeffrey E.
    Cortes, Jorge E.
    Hogge, Donna E.
    Tallman, Martin S.
    Kovacsovics, Tibor J.
    Damon, Lloyd E.
    Komrokji, Rami
    Solomon, Scott R.
    Kolitz, Jonathan E.
    Cooper, Maureen
    Yeager, Andrew M.
    Louie, Arthur C.
    Feldman, Eric J.
    BLOOD, 2014, 123 (21) : 3239 - 3246
  • [7] Determination of total and encapsulated drug pharmacokinetics for CPX-351, a nanoscale liposomal fixed molar ratio of cytarabine-daunorubicin (Cyt:Daun)
    Ciofani, Travis
    Harasym, Troy
    Juan, Michael C. Y.
    Mayer, Lawrence
    Cabral-Lilly, Donna
    Xie, Sherwin
    CANCER RESEARCH, 2011, 71
  • [8] Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts
    Lim, Wah-Seng
    Tardi, Paul G.
    Dos Santos, Nancy
    Xie, Xiaowei
    Fan, Mannie
    Liboiron, Barry D.
    Huang, Xiaoping
    Harasym, Troy O.
    Bermudes, David
    Mayer, Lawrence D.
    LEUKEMIA RESEARCH, 2010, 34 (09) : 1214 - 1223
  • [9] Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts
    Lim, Wah-Seng
    Tardi, Paul G.
    Xie, Xiaowei
    Fan, Mannie
    Huang, Ruby
    Ciofani, Travis
    Harasym, Troy O.
    Mayer, Lawrence D.
    LEUKEMIA & LYMPHOMA, 2010, 51 (08) : 1536 - 1542
  • [10] A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia
    Absalon, Michael J.
    Breese, Erin H.
    Lee, Lynn
    O'Brien, Maureen M.
    Phillips, Christine L.
    Burns, Karen
    Mizukawa, Benjamin
    An, Qi
    Mangino, Jennifer
    Kaplan, Joel
    Norris, Robin
    Perentesis, John Peter
    BLOOD, 2018, 132
12